Targeting Memory T Cells in Type 1 Diabetes

Diabetes mellitus—advances and challenges in human β-cell proliferation

(2015) Peng Wang et al.   Nature Reviews Endocrinology

PD-L1–Driven Tolerance Protects Neurogenin3-Induced Islet Neogenesis to Reverse Established Type 1 Diabetes in NOD Mice

(2014) Rongying Li et al.   DIABETES

Low-Dose Otelixizumab Anti-CD3 Monoclonal Antibody DEFEND-1 Study: Results of the Randomized Phase III Study in Recent-Onset Human Type 1 Diabetes

(2014) Ronnie Aronson et al.   DIABETES CARE

Restoring the balance: immunotherapeutic combinations for autoimmune disease

(2014) D. E. Smilek et al.   Disease Models & Mechanisms

Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes

(2014) Michael J. Haller et al.   JOURNAL OF CLINICAL INVESTIGATION

The Effector T Cells of Diabetic Subjects Are Resistant to Regulation via CD4+FOXP3+ Regulatory T Cells

(2014) A. Schneider et al.   JOURNAL OF IMMUNOLOGY

Molecular regulation of effector and memory T cell differentiation

(2014) John T Chang et al.   NATURE IMMUNOLOGY

The immune checkpoint inhibitors: where are we now?

(2014) Rachel M. Webster   NATURE REVIEWS DRUG DISCOVERY

Glycemic Control and Excess Mortality in Type 1 Diabetes

(2014) Marcus Lind et al.   NEW ENGLAND JOURNAL OF MEDICINE

Co-Inhibitory Pathways and Their Importance in Immune Regulation

(2014) Naoka Murakami et al.   TRANSPLANTATION

Anti-CD3 clinical trials in type 1 diabetes mellitus

(2013) Anastasia G. Daifotis et al.   CLINICAL IMMUNOLOGY

PD-1, but Not PD-L1, Expressed by Islet-Reactive CD4 + T Cells Suppresses Infiltration of the Pancreas During Type 1 Diabetes

(2013) Kristen E. Pauken et al.   DIABETES

Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders

(2013) K. C. Herold et al.   DIABETES

Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study

(2013) P. Ambery et al.   DIABETIC MEDICINE

Autoimmune effector memory T cells: the bad and the good

(2013) Priyadharshini Devarajan et al.   IMMUNOLOGIC RESEARCH

Targeting co-stimulatory pathways: transplantation and autoimmunity

(2013) Mandy L. Ford et al.   Nature Reviews Nephrology

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial

(2013) Mark R Rigby et al.   Lancet Diabetes & Endocrinology

Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial

(2013) Stephen E Gitelman et al.   Lancet Diabetes & Endocrinology

Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs  -Cell Function

(2012) S. A. Long et al.   DIABETES

Immunology in the clinic review series: focus on type 1 diabetes and viruses: the role of viruses in type 1 diabetes: a difficult dilemma

(2011) K. T. Coppieters et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Anti-CD3 Therapy Promotes Tolerance by Selectively Depleting Pathogenic Cells while Preserving Regulatory T Cells

(2011) C. Penaranda et al.   JOURNAL OF IMMUNOLOGY

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial

(2011) Nicole Sherry et al.   LANCET

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

(2011) Tihamer Orban et al.   LANCET

Identification of a potent anti-IL-15 antibody with opposing mechanisms of action in vitro and in vivo

(2010) DK Finch et al.   BRITISH JOURNAL OF PHARMACOLOGY

Recurrence of Type 1 Diabetes After Simultaneous Pancreas-Kidney Transplantation, Despite Immunosuppression, Is Associated With Autoantibodies and Pathogenic Autoreactive CD4 T-Cells

(2010) F. Vendrame et al.   DIABETES

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass

(2010) B. Keymeulen et al.   DIABETOLOGIA

Etiology of Type 1 Diabetes

(2010) John A. Todd   IMMUNITY

The PD-1 pathway in tolerance and autoimmunity

(2010) Loise M. Francisco et al.   IMMUNOLOGICAL REVIEWS

Genetics, pathogenesis and clinical interventions in type 1 diabetes

(2010) Jeffrey A. Bluestone et al.   NATURE

Regulatory T cells exert checks and balances on self tolerance and autoimmunity

(2009) Kajsa Wing et al.   NATURE IMMUNOLOGY

Recurrence of autoreactive antigen-specific CD4+ T cells in autoimmune diabetes after pancreas transplantation

(2008) Elsa Laughlin et al.   CLINICAL IMMUNOLOGY

Homeostasis of Naive and Memory T Cells

(2008) Charles D. Surh et al.   IMMUNITY

Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways

(2008) Brian T. Fife et al.   IMMUNOLOGICAL REVIEWS

CD4 T cells, lymphopenia, and IL-7 in a multistep pathway to autoimmunity

(2008) T. Calzascia et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA